Skip to Content

Cefixime Pregnancy and Breastfeeding Warnings

Cefixime is also known as: Suprax

Medically reviewed on March 29, 2017

Cefixime Pregnancy Warnings

Cefixime has been assigned to pregnancy category B by the FDA. Animal studies failed to reveal evidence of fetal harm. There are no controlled data in human pregnancy. Cefixime is only recommended for use during pregnancy when benefit outweighs risk.

See references

Cefixime Breastfeeding Warnings

There are no data on the excretion of cefixime into human milk. Other cephalosporins are excreted into human milk in small amounts. While adverse effects are unlikely, the infant should be monitored closely. The manufacturer recommends considering temporary discontinuation of nursing during treatment with cefixime. Other cephalosporins have been classified as compatible with breast-feeding by the American Academy of Pediatrics.

See references

References for pregnancy information

  1. "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc, Baltimore, MD.
  2. Ramus RM, Sheffield JS, Mayfield JA, Wendel GD Jr "A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy." Am J Obstet Gynecol 185 (2001): 629-32

References for breastfeeding information

  1. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 5th ed." Baltimore, MD: Williams & Wilkins (1998):
  2. "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc, Baltimore, MD.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide